







Title of Document: EFFECT OF CHITOSAN ON THE 
INDUCTION OF DNA DAMAGE RESPONSE 
BY SELENIUM COMPOUNDS. 
  
 
Shu Zhang, Master of Science, 2009 
  
Directed By: Assistant Professor, Dr. Wen-Hsing Cheng, 




Selenium (Se)， a nutrient trace mineral, plays important roles in optimizing human 
health. Chitosan is an effective, natural-oriented material for synthesizing nanopolymers, 
with preferable properties such as biocompatibility, biodegradation and resistance to 
certain enzymes. In this study, encapsulated Na2SeO3 and methylseleninic acid (MSeA) 
with low and medium molecular weight chitosan were used to determine the efficacy of 
Se in mitigating tumorigenesis. We applied Se compounds, which is from sub-lethal to 
lethal dose, to colon cancer cell line HCT-116 and normal fibroblasts cell line MRC-5. 
Analysis of cellular selenium content demonstrated that: 1) Na2SeO3, but not MSeA, 
treatment resulted in a greater Se retention in HCT-116 than in MRC-5 cells, 2) chitosan 
 
 
encapsulation enhanced Se contents in cells treated with the various Se preparations. Cell 
survival analysis showed that chitosan encapsulation protected HCT-116 and MRC-5 
cells from Na2SeO3 or MSeA induced toxicity. Moreover, this beneficial effect was 
greater in MRC-5 cells. MSeA encapsulated with chitosan induced phosphorylated ATM 
Ser-1981 formation in MRC-5 and HCT-116 cells to a less extent as compared to MSeA 
alone treatment. Taken together, the results suggest that, when encapsulated with 
chitosan, cells are less susceptible to Se treatment, possibly through a mechanism by 
which the presence of chitosan attenuates Se-induced activation of ATM and 
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Chapter 1: Literature review 
 
 
1.1 Early studies on Selenium (Se) 
 
Se was first identified as a by-product of sulfuric acid production by a Swedish chemist 
Jons Jacob Berzelius in 1817 (Brown and Arthur, 2001). It is a non-metal trace element 
with the atomic number 34, and is in the same chemical family with oxygen, sulfur, 
tellurium, and polonium. Se exists in nature as a combination of inorganic (such as 
selenide, selenate, and selenite) and organic (such as selenomethionine and 
selenocysteine) forms.  
Se was known only as a toxicant (Fels and Cheldelin, 1949) until 1952 when a biological 
role of Se was discovered in microorganisms (Postgate, 1952). The nutritional 
essentiality of Se was identified by Schwarz and Foltz in a seminal report indicating that 
dietary Se supplementation is required to prevent liver necrosis in rats (Schwarz and 
Foltz, 1958). Later on, it was demonstrated that Se is an integral component required for 
glutathione peroxidase (GPX) activity (Rotruck et al., 1973; Flohe et al., 1973). Evidence 
supporting selenocysteine as the 21st amino acid was first shown in eubacteria and 
archaebacteria systems. Stadtman and colleagues metabolically labeled Clostridium 
sticklandii with 75Se and found that Se exists in proteins in the form of selenocysteine 
(Cone et al., 1976; Stadtman, 1989). Then, the Gpx1 gene was cloned from mice and 








The biological function of Se is primarily implemented through its incorporation into 
three forms of Se-containing proteins (Behne and Kyriakopoulos, 2001). First, Se can be 
non-specifically incorporated into methionine-rich proteins, such as those found in the 
Brazil nut (Gander et al., 1991). Second, Se can be specifically incorporated into 
selenoproteins. The key features of selenoproteins include the decoding of UGA codon as 
selenocysteine (Sec) residues and the requirement of a stem-loop secondary structure in 
the 3’-UTR region of selenoprotein mRNA, also known as Sec insertion sequence 
(SECIS). There are specific tRNA (Cys[Sec]-tRNA) for Sec and a RNA-binding protein 
complex that recognizes the stem-loop secondary structure and facilitates decoding the 
codon UGA, which would otherwise act as a stop codon (Bock et al., 1991). Third, there 
are specifically Se-containing proteins that sequester Se through an unknown mechanism, 
examples of which include the uncharacterized liver protein 56K (SLP-56) and the liver 
fatty acid binding protein (SLP-14) (Behne et al., 1994).  
By scanning the entire genome for SECIS, it was shown that there are a total of 25 
selenopoteins in humans (Kryukov et al., 2003). They include five glutathione 
peroxidases (GPX1-GPX4, GPX6), three iodothyronine deiodinases (DI1-DI3), three 
thioredoxin reductases (TR1-TR3), the 15-kDa selenoprotein (Sep 15), selenoprotein H, 
I, K, M, N, O, P, R, S, T, U, V and selenophosphate synthetase-2 (SPS2). Except for 
selenoprotein P, which has ten Sec residues, selenoproteins only contain a single Sec 




selenoproteins; for instance, substitution of Sec in TR-1 with a cysteine results in 
decreased enzymatic activity (Hatfield and Gladyshev, 2002; Lee et al., 2000). 
Of note, more than one-third of selenoproteins are known to exhibit antioxidant 
properties. The GPX family uses glutathione as a reducing equivalent to eliminate 
hydrogen peroxide, organic hydroperoxides and phospholipid hydroperoxides (Brigelius-
Flohe, 1999). The TR family controls the redox state of thioredoxin (Bjornstedtet al., 
1995). Although selenoprotein P, a major extracellular selenoprotein, is generally 
considered a Se carrier, it has been shown to eliminate phospholipid hydroperoxides and 
thus is considered as a selenoperoxidase (Saito et al., 1999; Takebe et al., 2002).  
 
1.3 Se as a dietary component promoting human health 
 
Se is essential for certain metabolic pathways that support optimal human health.  For 
example, dietary Se deficiency leads to cardiomyopathy seen in patients with Keshan 
disease, a childhood endemic disease occurring in part of China where the soil is 
deficient in Se (Guanqing, 1979). Recently, hypomorphic mutation in SECISBP2, a gene 
whose product influences selenoprotein synthesis, has been studied, the result of which 
suggest this gene a potential target for treating human hereditary diseases, such as thyroid 
hormone disorders (Dumitrescu et al., 2005). At nutritional or supranutritional levels, Se 
is known as a chemopreventive agent that counteracts tumorigenesis through cell cycle 




Se is one of the most extensively studied trace elements with cancer chemopreventive 
properties. In vivo, Se is capable of inhibiting cancer cell growth and inducing apoptotic 
cell death by inducing ROS (Reactive Oxygen Species)  formation via interaction with 
GSH. Excessive formation of ROS leads to cell cycle arrest and accumulated DNA 
damage in tumor cells (Lu et al., 1995); (Spallholz et al., 2001); (Stewart et al., 1999b). 
Several underlying mechanisms of such effect have been elucidated. Se-induced apoptosis 
in prostate cancer cells is dependent on p53 (Zhao et al., 2006); Se also alters cancer cells 
from apoptosis-resistant to apoptosis-prone (Hu et al., 2006); (Li et al., 2007). 
In addition, antioxidants can counteract selenite-induced apoptosis by eliminating ROS 
(Shen et al., 2001). Se compounds negatively affect carcinogen activation and 
metabolism through inhibition of phase I enzymes and induction of phase II enzymes, 
which subsequently induce cell cycle arrest (Ganther, 1999); (Harrison et al., 1997). In 
animal models, Se suppresses carcinogenesis, which is initiated by carcinogen treatment. 
Se is also capable of inhibiting colonial expansion of a carcinogen-transformed 
population (Combs and Gray, 1998).  
 
1.4 Se compounds as prevention for colon cancer 
 
Colon cancer is regarded as a severe threat leading to cancer-related death in Untied 
States. Accumulating evidence indicates that Se is an effective chemopreventive agent 
against colon cancer in human. The proposed mechanisms of Se on colon cancer include 
1) inhibition of cytosine methyltransferases (Fiala et al., 1998) and cyclooxygenase 




An organic form of Se, selenomethionine, inhibits growth of human colon cancer cell 
lines HCT116 through p53 mediated G2/M cell cycle arrest as well as apoptosis (Goel et 
al., 2006). In addition, activation of ERK (Extracellular Signal-Regulated Kinase) and the 
subsequent phosphorylation of RSK (Ribosomal S6 Kinase) and histone H3 have also 
been suggested as target of Selenomethionine (Goulet et al., 2007). cDNA microarrays 
reveal statistically significant changes of 50 genes after Se challenge, for example, CX26 
(connexin26) or DAP-1 (Death associated protein 1) etc., exists in Se treated HCT116 
cells.  
 
1.5 Effect of Se in counteracting ROS 
 
Anti-carcinogenic activity by selenium and its metabolites are correlated with the 
production of ROS. Although the ROS theory of aging was proposed 50 years ago, there 
have been no definitive studies to prove or disprove the theory.  ROS, such as 
superoxides, hydroxy free radicals, and hydrogen peroxides are widely dispersed in vivo 
(Harman, 1956); they are by-products of redox cycling during mitochondrial respiration, 
modification of protein-thiols and methionine mimicry (Jackson and Combs, 2008).  
ROS can also be generated from exogenous sources, for instance UV and ionizing 
irradiation (Finkel and Holbrook, 2000). Because GPX1 accounts for much of the H2O2-
eliminating activity of Se (Cheng et al., 1997), it is logical to address the ROS theory of 
aging by investigating Se and GPX1 activity. By comparing aged and juvenile rats, it has 
been suggested that GPX activity can be up-regulated during the aging process in an 




Nonetheless, available evidence has not conclusively identified a role of GPX1 in 
lifespan extension in mouse models (Ladiges et al., 2009). Interestingly, Gpx4-/-mice are 
embryonic lethal while Gpx4+/-mice exhibit extended lifespan, possibly because the 
spontaneous tumors in Gpx4+/-mice are more susceptible than wild-type mice to apoptosis 
induced by the intrinsic oxidative stress as a result of the loss of one Gpx4 allele (Ran et 
al., 2007). 
 
1.6 The ATM pathway in DNA damage response 
 
Ataxia-telangiectasia (A-T) was identified as an autosomal recessive disorder that is 
characterized by early onset progressive cerebellar ataxia, oculocutaneous telangiectasia, 
lymphoid tumors and susceptibility to bronchopulmonary disease (Boder, 1985). Several 
abnormalities such as cellular radio sensitivity, checkpoint defects and chromosomal 
instability are characteristics of A-T. In clinical study, A-T patients show 
immunodeficiency and insulin-resistant diabetes (Lavin and Shiloh, 1997). Genetically, 
A-T is attributed to ATM mutation. ATM is a Ser/Thr protein kinase and a member of 
phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family (Savitsky et al., 
1995).  
ATM functions by forming a complex with MRE11–RAD50–NBS1 (MRN). Nijmegen 
breakage syndrome (NBS1 mutantions) and A-T-like disorder (MRE11 mutations) have 
certain symptoms in common with A-T (Carney et al., 1998); (Matsuura et al., 1998); 
(Varon et al., 1998); (Stewart et al., 1999a). As described by Lavin’s research group, 




DSBs) and signals to the DNA damage checkpoint to repress cell proliferation and 
facilitate DNA repair. In A-T cells, loss of γH2AX (Phosphorylated Histone H2AX) foci 
leads to failure of DNA fraction repair, whereas non-homologous-end-joining (NHEJ) 
repairs DNA DSBs in an ATM-independent manner.  
Mechanisms of DNA damage repair with rapid recruiting of repair proteins to accurate 
foci have been elucidated gradually. As for DSBs repair, the MRN complex recognizes 
damaged foci and its accumulation regulated by the mediator of DNA-damage 
checkpoint protein-1 (MDC1) adaptor protein. Thereafter, ATM localizes to the DSBs 
foci and associates with MRN complex at this initial repair stage, which guarantees 
complete activation of ATM and γH2AX is phosphorylated as downstream substrate of 
ATM. However, P53 was proved firstly to be substrate of incompletely activated ATM 
both in vitro and in vivo (Banin et al., 1998); (Canman et al., 1998); (Khanna et al., 
1998). To date, up to 700 phosphoproteins have been identified as targets of ATM 
(Matsuoka et al., 2007); (Linding et al., 2007). 
The order in which those DNA repair proteins assemble in ATM signaling pathway is 
postulated as: ATM phosphorylate histone variant of γH2AX to produce γH2AX initially. 
A second DSBs response protein MDC1 binds to γH2AX via breast cancer susceptibility 
protein-1 (BRCA1) C-terminal (BRCT) domain and this is key step for recognition and 
repair DNA damage. NBS1, as a component of MRN complex, localizes to breaks in the 
same manner as MDC1. The RING-finger ubiquitin ligase RNF8 ubiquitylates γH2AX 
and facilitates the accumulation of p53-binding protein-1 and BRCA1 by interacting with 
phosphorylated MDC1. Of interest, ATM plays a key role to phosphorylate a series of 




As an essential role in mediating DSBs, ATM undergoes autophosphorylation on at least 
three sites (Ser367, Ser1893, Ser1981) during activation process. In addition, DNA DSBs 
induce the acetylation of ATM in parallel to Ser1981 is another post-translational 
modification of ATM as well (Sun et al., 2005). Exceptions are examples from human 
cells, in which ATM can be activated without phosphorylation on Ser1981 (Hamer et al., 
2004); (Powers et al., 2004). Thus the phosphorylation of ATM could be relevant to the 
nature of stimulus.  
Treated with ATM small interfering RNA (siRNA), selenite induced apoptosis has been 
alleviated in mouse embryonic fibroblast NIH 3T3 cells, implying an involvement of 
DNA damage regulator ATM. In the same study, selenite also stimulates Ser-139 
phosphorylation of the ATM/ATR substrate H2AX (Zhou et al., 2003). It is likely that 
the selenite-induced apoptosis is attributed to ATM mediated cell damage. 
 
1.7 Chitosan as a favorable material to incorporate selenium as nanopolymer 
 
Chitosan is found in the exoskeleton of crustaceans of marine arthropods and insects, 
which is available in abundant supply. Several properties make it as a favorable material 
for synthesizing nanopolymer: it is non-toxic, biocompatible and biodegradable, yet 
resistant to enzymatic degradation in normal biological environment (Chandy and 
Sharma, 1990).  
In biochemical aspect, it is polysaccharide β (1–4) 2-amino-2-deoxy-D-glucosemodified 
from chitin, which is converted to chitosan by alkaline deacetylation Co-polymer of N-




in the molecular weight (5–2000 kDa) and degree of N-acetylation (40–98%), depending 
on the processing method [Cancer, chitosan nanoparticles and catalytic nucleic acids 
(Hejazi and Amiji, 2003). Common techniques established to produce chitosan include 
chemical cross-linking (Banerjee et al., 2002), emulsification solvent diffusion (Nafee et 
al., 2007), complex coacervation (Leong et al., 1998) and ionotropic gelation (Ma et al., 
2005). Due to the D-glucosamine residue with a pKa value of 6.2–7.0, chitosan can only 
be soluble in acid pH solutions (Luangtana-anan et al., 2005). Also, its encapsulation 
efficiency and release profiles largely depend on the molecular weight. Previous study 
postulated that high molecular weight chitosan with a high deacetylation degree improves 
plasmid DNA encapsulation efficiency (Bozkir and Saka, 2004).  
The surface of chitosan is positive-charged, thus it is able to deliver drugs/genes 
specifically to negative-charged tumor cells and enter the nucleus directly (Chitosan 
microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic 
metastatic model of osteosarcoma). Moreover, it releases drugs/gene in a suspending 
manner (Zhang and Neau, 2001). 
 In vitro degradation of chitosan by a commercial enzyme preparation: effect of 
molecular weight and degree of deacetylation]. Mucoadhesive property of chitosan 
enhances drug absorption, simply by re-arranging the junction proteins (Illum et al., 
1994); (Pan et al., 2002). In another word, it can overcome the permeability barrier posed 
by the epithelia, attributing to taking up of endosomes (Sakuma et al., 2001). Chitosan is 
able to induce apoptosis of bladder tumor cells by activating caspase-3 or other yet 




al., 2001). In addition, it suppresses growth of hepatocellular carcinoma to a certain 
extent (Qi et al., 2007). 
Seleno-short-chain chitosan (SSCC, molecular weight between 5,000 and 10,000 Da) 
inhibit proliferation of human leukemia K562 cells in a dose-dependent and time-
dependent manner. K562 treated by SSCC was primarily accumulated in G (2) /M phase, 
which is evidenced by flow cytometry analysis. Subsequently, this arrested growth is 
associated with K562 cell apoptosis (Liu et al., 2008). 
Packed siRNA by sodium tripolyphosphate (TPP)–chitosan nanoparticles demonstrated 
comparable gene silencing effects compared with Lipofectamine 2000 transfections. 
However, based on MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay for cytotoxicity, less than 50% cell death was observed, which was not expected 
result from gene knockdown. The conflicting data calls for further investigation to 
siRNA-chitosan nanoparticles as a potential therapeutic, especially in terms of tumor 
growth inhibition and normal tissue protection (Katas and Alpar, 2006).  
Besides delivery of siRNA as gene therapy, the docetaxel-loaded hydrophobically 
modified glycol chitosan (DTX-HGC) nanoparticles has been reported to facilitate 
antitumor efficacy of free DTX, inducing less tumor volume and increased survival rate 
in A549 lung cancer cells-bearing mice and reduced the anticancer drug toxicity 
compared to that of free DTX (Hwang et al., 2008). 
 





Based on findings in 2003 (Zhou et al., 2003), selenium compound sodium selenite 
triggers ATM mediated apoptosis in NIH3T3 mouse embryonic fibroblast cells. 
Moreover, sodium selenite phosphorylated Ser-139 of ATM substrate H2AX in HL60 
cells. Therefore, it is suggested that selenium induces fibroblast apoptosis, which can 
attribute to DNA damage and subsequently activation of ATM pathway. In addition, 
specific phosphorylation site can be altered by treatment of selenium. 
Since chitosan-nanopolymers have been proved to be an efficient delivery of gene 
therapy drugs and chemical compounds such as siRNA and selenium. Of note, the 
seleno-short-chain chitosan (SSCC) exert anticancer effect on K562 cells by arresting cell 
growth. In our lab, we have recently identified novel barriers of tumorigenesis induced by 
selenium compounds, namely senescence and DNA damage response.  
Collectively, the activation of tumorigenesis barriers is thought to attribute to the toxic 
aspects of suspernutritional level of selenium. To address this issue, we aim at providing 
a targeted delivery of selenium to colon cancer cells. Since cancer cell surface is negative 
charged; in contrast, chitosan particles own positive surface charges. Hence, we raise a 
question that whether Chitisan-Se has influence on the efficacy of Se delivery and on the 
activation of tumorigenesis barriers, for example, the phosphorylation of DNA damage 
repair factor ATM. 
In combination of chitosan-coated selenium and DNA damage repair, this study mainly 
focuses on effect of chitosan selenium nanopolymer on cell viability, oxidative stress 
generation and DNA damage associated ATM pathway. Here we compare effect of 
chitosan conjugated sodium selenite, methylseleninic acid and original selenium 




To unveil the difference between normal and cancer cell in response to Chitosan-
selenium and original selenium, this research includes assessment on cell survival, ROS 
production and ATM Ser 1981 phosphorylation. 
 
Figure 1.1 Eluciated mechanisms underlying Se induced cancer cell apoptosis and 
unknown mechanisms we investigate. 




Chapter 2: Review: Selenoproteins and the aging brain (Review 
paper accepted in 2009) 
 
 
2.1 Selenium in the brain  
 
In addition to the well-documented functions of Se in the antioxidant system and in the 
regulation of the thyroid and immune function (St Germain et al., 2009), recent advances 
have indicated a role of Se in the maintenance of brain function. Se is widely distributed 
throughout the body, but is particularly well maintained in the brain, even upon 
prolonged dietary Se deficiency (Schweizer et al., 2004). In the brain, the highest 
concentration of Se was found in the gray matter, an area responsible for chemical 
synaptic communication (Hock et al., 1975). It has been shown that rats on a Se-deficient 
diet for thirteen weeks retained Se in their brain, while their plasma Se concentrations 
were depleted (Prohaska and Ganther 1976). After intraperitoneal injection of 75SeO32- 
into Se-deficient rats, the brain rapidly sequesters a large portion of the available Se 
(Trapp and Millam 1975). In the brain, it was found that the cerebellum accumulated the 
highest concentration of Se, followed by the cortex, medulla oblongata, cerebral 
hemisphere, and the spinal cord. Interestingly, Se retention in the brain depends on 
selenoprotein P (Nakayama et al., 2007).  
Because the body preferentially allocates available Se to the brain during Se deficiency, 
Se may play an essential role in the brain. More evidence for the brain being at the apex 




caused a more than 99% reduction of Se concentration in the liver, blood, skeletal tissue, 
and muscle, while the brain retained only 60% of the Se, even under generational Se 
deficiency (Kyriakopoulos et al., 2000). Likewise, the mRNA level of twelve 
selenoproteins in young pigs fed a Se-deficient diet remains highly expressed in the 
pituitary gland, but is significantly reduced in other organs such as the liver (Zhou et al., 
2009). Moreover, Se concentration in Alzheimer’s brains was found to be 60% of the 
age-matched control individuals (Hawkes and Hornbostel, 1996). These results suggest 
that Se is critical for the maintenance of brain function, and is appropriated to the brain 
from the remaining part of the body even when the body Se availability is scarce. 
 
2.2 Selenoproteins and neurodegeneration 
 
Evidence suggests a link between Se and neuronal disorders via redox regulation. Low 
levels of Se are associated with cognitive impairment, depression, anxiety and hostility 
humans (Rayman and Rayman 2002), and Se deficiency was found to be associated with 
decreased expression of brain-derived neurotrophic factor mRNA in the developing brain 
of rat pups (Mitchell et al., 1998). Increased oxidative stress has been linked to neuronal 
disorders (Rosen, 1993), including Alzheimer’s disease (Ishrat et al., 2009), multiple 
sclerosis, Batten’s disease, Parkinson’s disease and brain tumors (Chen and Berry, 2003; 
Schweizer et al., 2004). In particular, Alzheimer’s disease is characterized by memory 
loss with age, a symptom that is linked to ROS-induced neuron damage. Levels of Se are 
elevated in amygdala (Cornett et al., 1998) and in microsomesin the temporal lobe of 




dementia caused by Alzheimer’s type revealed that total GPX activity and Se content in 
the plasma decreased with age in the patients (Ceballos-Picot et al., 1996; Basun et al., 
1991). Likewise, hematogenous cells derived from patients suffering from multiple 
sclerosis and Batten's disease show lowered Se concentration and decreased GPX activity 
(Clausen et al., 1988). Furthermore, the level of Se in the plasma is decreased in patients 
with malignant tumors of central nervous origins (Philipov and Tzatchev, 1988). 
Intriguingly, long-term culture of neuronal cells requires medium conditions of basal 
elements supplemented with either serum or Se (Tian et al. 2002). 
 
Figure 2.1 Function of ROS in the aging brain as a consequence of selenium status.  Most 
brain related neurodegenerative diseases have increased free radical production, and 
decreased radical scavenging.  
 
Considering the location of antioxidant activity in the brain, some functionally 
characterized selenoproteins have been postulated to protect against neurodegeneration 
via redox regulation. The selenoproteins that are implicated in brain maintenance include 




selenoprotein M (Korotkov et al., 2002; Steinbrenner and Sies, 2009; Drukarch et al., 
1998; Dringen et al., 1999; Whanger, 2001; Jeong et al., 2002). Compared with age-
controlled normal individuals, Alzheimer’s patients showed a significant age-dependent 
decrease in the Se-dependent glutathione peroxidase activity in the plasma and red blood 
cells (Ceballos-Picot et al., 1996). Moreover, an increase in thioredoxin reductase activity 
has been observed in the brain of Alzheimer’s patients (Lovell et al., 2000). In contrast, a 
recent report showed that the level of Se in plasma and cerebrospinal fluid from 
Alzheimer’s patients are comparable to normal individuals (Gerhardsson et al., 2008). 
Thus, changes of the selenoenzyme activities appear to be confined to the brain. 
Parkinson’s disease is another age-related degeneration characterized by loss of the 
dopaminergic cells caused by the formation of ROS through dopamine’s own metabolism 
(Kupsch and Oertel, 1994).  The link between selenoproteins and Parkinson’s disease is 
an emerging field of study. Using the 6-OHDA-treated rats as a model of Parkinson’s 
disease, it was found that administration of Se increased antioxidant activity, thus 
protecting the dopaminergic cells from oxidative damage.  Consequently, more dopamine 
cells were able to survive after Se treatment (Zafar et al., 2003). Neuronal systems 
experiencing acute stress, such as epilepsy and stroke, exhibit lowered GPX activity in 
plasma and decreased GPX4 activity in neuronal cells (Ramaekers et al., 1994; Weber et 
al., 1991). In animal models, selenoprotein P knockout mice exhibit reduced growth and 
develop ataxia, as well as decreased GPX and TR activities in the brain (Schomburg et 
al., 2003). Transgenic mice that overexpress human GPX1 showed decreased 






Figure 2.2 Peroxide-eliminating selenoproteins involved in various neurodegenerative 
diseases.  Selenium is thought to confer free radical scavenging abilities in the brain by 
its incorporation into selenoproteins.  Some selenoproteins are tissue specific, while 
others are more general. 
 
2.3 The Se-dependent glutathione peroxidase 
 
The mammalian GPX was originally identified as an antioxidant enzyme that protects 
membrane lipids and macromolecules from oxidative damage in 1957 (Mills, 1957). To 
date, there are five Se-dependent GPXs known to exist in mammals: the cytosolic GPX1, 
GPX2 (also known as gastrointestinal GPX), GPX3 (or plasma GPX), GPX4 (or 
phospholipid hydroperoxide GPX), and the newly identified GPX6.  
Systematic investigations revealed that in human and rodent brains, GPX1 is ubiquitously 
expressed in both neurons and glial cells, and functions as a ROS scavenger. It is known 




regions in patients suffering from Parkinson’s disease (Damier et al., 1993; Takizawa et 
al., 1994). Furthermore, by employing the Alzheimer's disease related (APP) transgenic 
mice, a recent study demonstrated that the GPX activity can protect against oxidative 
stress induced by neurotoxic agents in the hippocampus (Garcia et al., 2009). From a 
nutraceutical perspective, extracts of panax ginseng, a Korean red ginseng, has been 
shown to activate GPX activity and protect against transient cerebral ischemia-induced 
brain damage in the rats (Kim et al., 2009). In contrast, another study showed that 
overexpression of GPX1 in mice does not improve neurogenesis in juvenile mice that 
have sustained brain injury (Potts et al., 2009).  
GPX1, the most abundant Se-dependent GPX, is expressed in various types of neuronal 
cells including neurons, astrocytes, and glial cells (Lindenau et al., 1998; Takizawa et al., 
1994). Using primary cultured neurons isolated from Gpx1-/- mice, it was shown that 
GPX1 protects against H2O2 induced oxidative stress and the toxicity of amyloid β (Aβ) 
peptides, the major component of senile plagues and cause of Alzheimer’s disease (Crack 
et al., 2006). In contrast, it was reported that Gpx1-/- mice are more resistant to kainic acid 
induced seizure and neurodegeneration (Jiang et al., 2000). As such, further studies are 
needed to elucidate the role of GPX1 in response to various types of brain damage in 
different regions. 
In rats, cortical neurons and astrocytes are prone to oxidative stress induced by paraquat 
(Schmuck et al., 2002). The first identified phenotype of Gpx1-/- mice was an increased 
susceptibility to acute paraquat-induced lethality (Cheng et al., 1998). This suggests a 
role for GPX1in the protection against brain damage. The GPX1 protein is highly 




hallmark features of Parkinson’s disease and dementia (Power and Blumbergs, 2009), 
suggesting that GPX1 is involved in the degradation of the Lewy bodies. 
GPX4 is a multifunctional selenoprotein expressed as cytosolic, mitochondrial, and 
nuclear isoforms. Compared to the tetrameric GPX1, GPX4 is a monomer and eliminates 
phospholipid hydroperoxides (Ursini et al., 1985). GPX4 and vitamin E may work 
together to suppress lipid peroxidation on biological membranes and lipoproteins (Ursini 
and Bindoli, 1987). Although Gpx4-/- mice are embryonic lethal, embryonic fibroblasts 
derived from Gpx4-/- mice are hypersensitive to inducers of oxidative stress, including γ-
irradiation, paraquat, tert-butyl hydroperoxide, and hydrogen peroxide (Yant et al., 2003). 
In adult brains, mitochondrial and cytosolic GPX4 isoforms are mainly expressed in 
neuronal cells, but are not expressed in glial cells, as evidenced by 
immunohistochemistry and mRNA analyses (Savaskan et al., 2007).  GPX4 is up-
regulatedin response to brain injury only in regions of the brain surrounding astrocytes, 
not in other regions of the brain such as those with a high density of neurons.  Savaskan 
and colleagues postulated that up-regulation of GPX4 in the astrocytes protected brain 
cells from apoptosis. Mutations in DJ-1 cause autosomal recessive, early-onset 
Parkinson’s disease. Because DJ-1 binds GPX4 mRNA and suppresses the protein 
expression at the post-transcriptional level, GPX4 protein level is up-regulated in the DJ-
1 deficient Parkinson’s disease (Blackinton et al., 2009). Moreover, GPX4 has been 
proposed as a sensor of oxidative stress in neuronal cells, triggering the 12/15-
lipoxygenase derived lipid peroxidation and apoptosis-inducing factor-mediated cell 
death pathways (Seiler et al., 2008). Consistent with this, Gpx4+/- mice accumulate beta-




suggesting an increased amyloid plaque burden, a hallmark of Alzheimer’s disease (Chen 
et al., 2008). Overexpression of the mitochondrial form of GPX4 reverses the retardation 
phenotype in the developmental brain of the guanine-rich sequence-binding factor 1 
(Grsf1) knockout mice, suggesting that GPX4 plays an important role in the embryonic 
brain development (Ufer et al., 2008). Similarly, GPX4 has been shown to eliminate 
excessive oxidants and amyloid plaques in primary cortical neurons isolated from Gpx4 
overexpression mice (Ran et al., 2006). Moreover, GPX4 is highly expressed in neurons 
located at olfactory bulb, hippocampus, cerebral cortex, and cerebellar cortex in mice 
(Zhang et al., 2008). Knockdown of mitochondrial GPX4 in mice resulted in impaired 
development due to apoptosis in the cerebral cells in the hindbrain (Borchert et al., 2006). 
In conclusion, GPX1 and GPX4 may collectively eliminate various types of oxidants in 
the brain. 
 
2.4 Thioredoxin reductases 
 
Thioredoxin reductases (TR) belong to a family of selenoproteins that regulate the redox 
status of thioredoxin (Txn) (Arner and Holmgren, 2000). The Txn-dependent system has 
been implicated in the age-related degeneration such as Alzheimer’s and Parkinson’s 
disease (Andersen, 2004). There are three members of TR in mammals: the cytosolic 
thioredoxin reductase (TR-1) (Gladyshev et al., 1996), the mitochondrial thioredoxin 
reductase (TR-2) (Gasdaska et al., 1999), and the thioredoxin-glutaredoxin reductase 
(TR-3) (Sun et al., 2001a). While TR-1 and TR-2 are expressed ubiquitously, TR-3 is 




catalytically interacting reactive centers. The redox active site, located in theC-
terminal,contains a selenocysteine residue; therefore thioredoxin reductase activity can be 
modified by dietary Se (Soerensen et al, 2008). Not surprisingly, the expression and 
activity of TR are maintained in the brain under Se deficiency (Schomburg et al., 2003).  
Homozygous mutants of TR can cause embryonic death at the blastocysts stage (Matsui 
et al., 1996); however, embryos taken from Txnrd2-/- mice 10.5 days postcoitus show 
severe neuronal pathologies, like anterior neural tube defects (Nonn et al., 2003). Using 
neuron system specific Txnrd1-/- or Txnrd2-/- mice, it was found that the Txnrd2-/- mice 
appear normal, while Txnrd1-/- mice have ataxia, tremor, and a smaller body size 
(Soerensen et al., 2008). At the cellular level, the Txnrd1-/- mice with TR-1 knockout only 
in the neuron cells develop impaired Bergmann glia and neuronal precursor cells, as well 
as hypoplasia in various regions in the brain. Moreover, the following reports suggest that 
TR-1 and TR-2 are required for brain development and the maintenance of redox status in 
the brain. First, TR-1 in embryos has highest expression in neuronal tissues such as the 
developing forebrain, rhombomeres and the neural tube (Kanemasa et al., 1992). Second, 
mice with a brain-specific knockout of Txnrd1, the gene that encodes TR-1, are viable, 
but exhibit growth retardation and a movement disorder attributed to cerebellar 
dysfunction (Tronche et al., 1999).  
Incubation of neuronal PC-12 cells with the TR inhibitor 1-chloro-2,4-dinitrobenzene 
(CDNB) resulted in elevated ROS levels and in the activation of the c-Jun N-terminal 
kinase and mitogen activated protein kinase 4 stress response signaling pathway 
(Seyfried and Wullner,  2007). Thus, TR is considered as a therapeutic target for ROS-




light resulted in an increase in the TR protein expression, increased nuclear translocation 
of the protein, and the binding of Nrf2 to the antioxidant response element of TR mRNA 
(Tanito et al., 2007). Furthermore, treatment of the mouse photoreceptor-derived 661W 
cells with 4-hydroxynonenal, a lipid peroxide, alleviated H2O2-induced cell damage and 
increased TR expression in an Nrf2-dependent manner. Hence, the interaction between 
TR and the Nrf2-ARE pathway could be the target of 4-HNE‘s therapeutic ability. 
 
2.5 Selenoprotein P 
 
Selenoprotein P is central to Se homeostasis in mammals and is considered a reliable 
biomarker for total body Se status (Hill et al., 1996; Burk and Hill, 2005). Because 
selenoprotein P contains ten Sec residues and is estimated to store 60% of the Se in 
plasma; it is considered as a Se transporter that can sequester a large portion of 
extracellular Se (Hill et al., 1996; Brown and Arthur, 2001; Burket al., 1991). 
Selenoprotein P issecreted primarily from the liver as a glycoprotein and is associated 
with the ApoER2 liporeceptor in humans and mice (Read et al., 1990; Takebe et al., 
2002). Interestingly, results from mouse studies have suggested an epistatic effect of 
selenoprotein P and ApoER2 on the maintenance of brain function. The SelP-/- mice or 
the ApoER2-/- mice fed a Se-deficient diet manifest features of neuronal disorders, and the 
ApoER2-/-mice have more severe symptoms than theSelP-/- mice (Nakayama et al., 2007). 
The N-terminal domain of selenoprotein P contains one Sec residue in the UxxC redox 
motif (U, Sec; C, Cys), while the C-terminal domain contains nine Sec residues. In rats, 




resultingfrom differential splicing in the C-terminal region (Himeno et al., 1996). 
Selenoprotein P also differs from others selenoproteins because it contains two SECIS 
elements in the 3’-UTR of the mRNA (Read et al., 1990).  
Selenoprotein P plays a central role in Se homeostasis and is necessary for optimal health 
in the brain (Nakayama et al., 2007). In humans, selenoprotein P mRNA expresses in 
cerebrospinal fluid, neurons, fiber tracts, and ependymal cells (Scharpf et al., 2007). 
Interestingly, selenoprotein P was found to be the neuronal survival-promoting factor in 
fractionated bovine serum (Yan and Barrett, 1998). Moreover, genomic analysis suggests 
that selenoprotein P single nucleotide polymorphisms are associated with the risk of 
glioma pathogenesis (Rajaraman et al., 2009). The Se rich, C-terminal selenoprotein P is 
required to prioritize body Se to the brain (Nakayama et al., 2007). This is consistent with 
the view that optimal selenoprotein expression and activity can be maintained in the brain 
even though the body Se status is depleted.Thus, Se in the brain may function 
independently from Se residing in other regions of the body.Selenoprotein P can be 
synthesized and secreted from cultured rat and human astrocytes (Yang et al., 2000; 
Steinbrenner et al., 2006a). Interestingly, mice with targeted disruption of the 
selenocysteine tRNA gene transcription activation factor (STAF) or selenoprotein P 
display overlapping neurological phenotypes to a great extent (Carlson et al., 2009). 
Moreover, there is an 80% reduction in selenocysteine tRNA level in the brain of the Staf-
/ mice.  
Selenoprotein P has also been linked to the protection against Alzheimer’s disease. 
Analysis of the postmortem Alzheimer’s brain by immunohistochemistry demonstrated 




where levels of oxidative stress are high (Bellinger et al., 2008). Thus, selenoprotein P 
may act as an antioxidant to protect against the damage in the Alzheimer’s brain. 
Likewise, it has been shown that selenoprotein P protects astrocytes against oxidative 
stress induced by tert-butyl hydroperoxide (Steinbrenner et al., 2006b).  
Sepp1-/- mice fed with a Se-deficient diet show increased severity in motor impairment, 
rotarod test and pole climb compared to the control group (Hill et al., 2004). Sepp1-/- 
mice have dystrophic and degenerated axons in their brainstems and cervical spinal cords 
regardless of the Se level in the diet. Sepp1Δ240–361 mice fed a Se-deficient diet exhibited 
less severe neurodisorders than Sepp1-/- mice (Hill et al. 2007). Moreover, brain Se 
concentrations are significantly decreased in the Sepp1Δ240–361 mice, whereas Se contents 
in the liver and kidney remain comparable to wild-type mice. Since the region between 
amino acid residues 240-361 in selenoprotein P includes several Sec residues, the results 
from using the Sepp1Δ240–361 mice indicate critical roles of the Sec residues, in 
selenoprotein P, in Se retention of brain and optimal health. 
 
2.6 Selenoprotein W 
 
Selenoprotein W was originally purified in cytosol from the liver of lambs, and since has 
been known to prevent white muscle disease in domestic animals (Vendeland et al., 1993; 
Whanger, 2000). The glutathione molecule shows intrinsic affinity to selenoprotein W 
(Dringen et al., 1999), which may explain why this selenoprotein is capable of reducing 
protein disulfide bonds in the Escherichia coli cytoplasm (Prinz et al., 1997), as well as 




selenoprotein W exists in many tissues, its expression is preserved in the brain under Se 
deficiency in rats (Yeh et al., 1997). In particular, the expression of selenoprotein W in 
cortex, cerebellum, and thalamus remained constant under Se deficiency (Sun et al., 
2001b). Thus, selenoprotein W expression is maintained in certainregions of the brain in 
response to different stages of Se deficiency, suggesting a role of selenoprotein W in 
redox regulation in the brain. 
Experiments employing cultured neuronal cells have indicated a role of selenoprotein W 
in the brain.Increased expression of selenoprotein W protects the rat glial cells against 
oxidative stress induced by heavy metal or the 2, 2’-Azobis (2-amidinopropane) 
dihydrochloride (AAPH) (Sun et al., 2001c; Amantana et al., 2002). Treatment of SH-
SY5Y neuronal blastoma cells with methylmercury,a neurotoxicant, results in decreased 
selenoprotein W mRNA expression in a glutathione dependent manner (Kim et al., 2005).  
Recently, high levels of selenoprotein W mRNA and protein expression have been found 
in the developing central nerve system of rodents (Chung et al., 2009). Collectively, these 
results suggest selenoprotein W cansafeguard developing neuronal cells from oxidative 
attack of endogenous and exogenous origins.  
 
2.7 Selenoprotein H 
 
Selenoprotein H is a newly discovered 14-kDa nucleolar protein expressed primarily in 
the thymus and brain, but also during embryogenesis and tumorigenesis (Novoselov et 
al., 2007). Similar to other selenoenzymes, selenoprotein H shares the conserved CXXU 




ofDrosophila melanogaster embryos (Morozova et al., 2003), and can protect H22 
neuronal cells against UV-induced DNA damage and superoxide production (Ben et al., 
2007). Although the physiological function of mammalian selenoprotein H is largely 
unknown, these results suggest a role of this selenoprotein in the brain as an antioxidant. 
 
2.8 Selenoprotein M 
 
Selenoprotein M is a newly identified selenoprotein containing a SECIS distinct from 
other selenoproteins; it lacks the invariant adenosines typically found in SECIS 
(Korotkov et al., 2002). Based on the study, the secondary structure of selenoprotein M is 
similar to Sep15, selenoprotein W and selenoprotein T. Selenoprotein M mRNA is 
expressed in various tissues in mice, butbrain has the highest levels. Recent results 
suggest that selenoprotein M may regulate the pathogenesis of Alzheimer’s disease. 
Overexpression of the human selenoprotein M in rats causes a redox shift resulting in a 
reduced redox status in the brain. The induction of the ERK signaling, which is 
associated with the inhibition of alpha/gamma secretase-mediated proteolysis and the 
phosphorylation of the Tau protein at several residues, also resulted from selenoproteins 
M overexpression in rats (Yim et al., 2009). These responses improve brain function, and 
may prevent the Alzheimer’s brain from sustained degeneration; thus suggesting a 






2.9 Perspectives on selenoproteins in neurological aging 
 
Se and selenoproteins are indispensable in the maintenance of the physiological functions 
of the brain, especially in attenuating neuron damage induced by oxidative stress. Based 
on previous studies in animal models and clinical trials, it is clear that selenoproteins, 
such as GPX, TrxR and SelP, have a critical role in protecting mammalian 
neurodegeneration either by eliminating ROS or by stimulating related antioxidant 
pathways. The body of evidence accumulated emphasizes the importance of 
selenoproteins in maintaining proper brain function; however, more data should be 
collected in the form of in vivo experiments.   
A fascinating perspective in the role of selenoproteins in neurological aging is their 
potential interaction with telomeres, a tandem TTAGGG repeat at chromosome ends. The 
length of the telomeres in cells derived from the hippocampus is longer In Alzheimer’s 
patients than in control individuals; however, in buccal and white blood cells from the 
same Alzheimer’s patients, the telomere lengths are significantly shorter than the control 
groups (Thomas, 2008).  Thus, Alzheimer’s patients have evolved unique mechanism for 
telomere maintenance. Recently, it was shown that a form of vitamin E could provide 
protection to telomeres in the aging brain (Tanaka, 2007). Tanaka and colleagues showed 
that age-dependent telomere shortening in human brain microvascular endotheliocytes is 
negated by phosphorylated alpha-tocopherol, possibly through alpha-tocopherol’s ability 
to decreaseintracellular oxidative-stress.  Given the antioxidant similarities between Se 
and vitamin E, it would be interesting to determine if Se had a similar effect in the brain 




prevents telomere length shortening during cellular aging in the normal human L-02 
hepatocyte (Liu et al., 2004).  There is, however, evidence that telomere shortening in the 
brain does increase the chances of developing atypical and malignant meningiomas and 
gliomas, pathologies more commonly associated with aged populations (Sanson and 
Cornu 2000). Altogether, future research is needed to elucidate the mechanism by which 
Se mediates telomere functions, in the brain. 
Another prospective avenue of a role of Se in the protection against aging brain could be 
independent from its role in decreasing oxidative stress; but as of yet, the collective body 
of evidence in the field has not produced sufficient results supporting this hypothesis.  
There has been evidence that suggests that Se associates with other minerals (Cakatay et 
al. 2008; Maret 2008; Liu et al. 2009).  Therefore, Se’s relationship with other minerals 
and vitamins could elucidate a novel role of Se in the aging brain.  This will provide a 









3.1.1 Cell lines 
 
Table 3.1 Cell lines 
Cell Description References 
MRC-5 Normal Human Fetal Lung Fibroblast (Jacobs et al., 1970)  
HCT116 Human Colon Cancer (Schroy et al., 1995)  
 
3.1.2 Chitosan and selenium compounds 
 












L1 Na2SeO3 3:1 350-450 
L2 MSeA 90-100 





3.1.3 Chemicals and reagents 
 
The major chemicals and reagents used in this research are listed in Appendix I 
 
3.1.4 Solutions and their ingredients 
 
Buffer, solution and gel were prepared according to the formulation listed in Appendix 
II.  
 
3.1.5 Commercial kits 
 
The main commercial kits used in this research are listed in Appendix III. 
 
3.1.6 Equipments and facilities  
 
All equipments and facilities have been provided by Department of Nutrition and Food 









A) Low and medium molecular weight chitosan (Sigma), sodium tripolyphosphate (TPP) 
(Pfaltz & Bauer) were of bio-analytical grade.  
Chitosan-TPP nanoparticles were prepared according to the ionotropic gelation process. 
In brief, chitosan was dissolved in 1% (weight /volume) equal volume of acetic acid 
(Fisher) under sonication until the solution was transparent. Different amount of sodium 
selenite (Sigma) or methylseleninic acid (Sigma) was dissolved together with chitosan in 
order to obtain the different mass ratio of chitosan/ selenium compounds (sodium 
selenite, methylseleninic acid). The ratio of chitosan to selenium compound was 3:1. 
Then, equal volume TPP aqueous solution was added dropwise to chitosan solution, 
which was stirred for 30 minutes at room temperature to obtain nanoparticles.  
B) Preparation of original selenium compounds 
Sodium selenite (SSe, Na2SeO3) and methylseleninic acid (MSeA, CH3SeO2H) were 
suspended in 1X phosphate-buffered saline (PBS) and dilute to work concentration as 
needed.  
 
3.2.2 Cell culture 
 
MRC-5 (Coriel) and HCT-116 (ATCC) were cell lines used in this study. MRC-5 were 
cultured in MEM (Minimum Essential Medium, Mediatech) with 15% fetal bovine serum 
(Sigma), 1ng/mL essential amino acid (Mediatech), 1ng/mL nonessential amino acid 
(Mediatech), 1ng/mL vitamins (Mediatech), 100U/mL penicillin/ strepcillin (Mediatech), 




5% CO2 incubator. HCT-116 cells were cultured in D-MEM (Dulbecco's Modified Eagle 
Medium medium, Mediatech) with 10% fetal bovine serum (Sigma), 100u/mL penicillin/ 
strepcillin (Mediatech), 100U/mL amphotericin B (Mediatech) and 5μg/mL plasimocin 
(InvivoGen).  
MRC-5 and HCT-116 were seeded in corresponding medium and cultured to 90% 
confluence. At second day, nano-selenium, original Na2SeO3, MSeA (Sigma) were 
applied to both cells lines in concentration of 0.3µM, 1µM, 3µM, and 10µM respectively, 
according to preliminary survival test. 
 
3.2.3 Selenium concentration assessment  
 
First, prepared samples were washed by 1XPBS for four times. Second, these cells were 
then dissolved in 3.0 mL-4mL of 0.2 mol/L NaOH (Mallinckrodf) and 0.2% SDS 
(Teknova), and protein was measured using the BCA (Brown et al., 1989) (bicinchoninic 
acid) kit (Thermo) following the instsruction. After that, cellular Se concentration was 
determined by hydride-generation atomic absorption spectrometry. Samples were treated 
for analysis by predigestion in nitric acid and hydrogen peroxide, followed by high-
temperature ashing in the presence of Mg(NO3)2 as an aid to prevent Se volatilization.  
 






MRC-5 and HCT-116 cells were seeded in 24-well plates (Greiner Bio-One) and treated 
by four selenium compound described in 2.1.2 and two chitosan control at above four 
dosages. Cells were incubated with reagents for 48 hours. At the end time point, cells 
were washed twice with 1XPBS and then incubated with 500 µL MTT (Calbiochem) at 
work concentration of 1mM for 3 hours. After incubation, MTT was dumped out and 
cells were washed twice with 1XPBS. DMSO (Mallinckrodt) was applied to each well at 
room temperature. Plates should be tapped lightly to mix DMSO and absorbed MTT 
well. Once MTT was dissolved in DMSO, plates were read directly by FLUOstar 
OPTIMA plate reader (BMG Labtech) at absorption wavelength of 595nm.   
 
3.2.5 Immunofluorescence assay 
 
HCT-116 and MRC-5 cells were cultured on coverslips in 6-well plates (Greiner Bio-
One) and treated the next day.  The cells then were washed with PBS once and fixed with 
4% paraformaldehyde (Fisher) for 15 min at room temperature and washed with 1XPBS 
once. The fixed cells were then permeabilized in 90% methanol (Pharmco AAPER) for 
10 min at -20°C and washed with 1XPBS once. Then cells were incubated with 0.3% 
Triton-100 (Calbiochem) for at room temperature for 10mins, then followed by three 
times’ washing with 1XPBS (5 min each time). After that, cells were blocked in 3% BSA 
(Calbiochem) in PBS for 1 hour. Wash samples with 1XPBS three times, for 5mins each 
time. The immunoblotting step was performed using primary antibodies of total ATM 
(Epitomics) and ATM-Ser1981 (Rockland) overnight at 4°C. After incubation, cells were 




immunofluorescence antibodies (1:200 for anti-mouse and anti-rabbit) (Invitrogen) in 
BSA for 1 hour at room temperature. Wash samples with 1XPBS three times. Antifade 
DAPI dye (Invitrogen) applied to the slide. A coverglass was mounted on top of the slide 
and sealed with nail polish. Prepared slides were observed under a Zeiss AxioObserver 
100 fluorescence microscope (Carl Zeiss) for image acquisition. Softwarae Axiovision 
4.7 (Carl Zeiss) was used to obtain the images. Fluorescence indicating nucleus was 
observed by using the filter cube set 49 for DAPI (exitation 365nm, filter 395nm, and 
emission 445nm), fluorescence indicating expression of total ATM protein by filter cube 
set 38 for GFP (exitation 470nm, filter 495nm, and emission 525nm) and fluorescence 
indicating expression of phosphorylated ATM Ser 1981 by filter cube set 43 for DsRed 
(exitation 550nm, filter 570 nm, and emission 605nm). Each individual treatment was 
taken 3 images, which under same magnification scale (630X) and exposure time 
(87.6ms for DAPI, 332.8ms for GFP and 450.2ms for DsRed). 
 
3.2.6 ROS assay 
 
MRC-5 and HCT-116 cells were seeded in black 96-well plate (NalgeNunc) and cultured 
for one day. Desired concentration of nano-selenium and original selenium were pipetted 
in wells and incubate for 9 and 24 h. Culture media was poured out and 1XPBS was 
added to wash cells once. Dump PBS and add 50 μl ROS dye 5-(and-6)-chloromethyl-2', 
7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen), 
which is a cell-permeate indicator for ROS. Final concentration of ROS dye should be 10 




Thereafter, ROS was incubated with samples for 40 min. After incubation, 5mL of lysis 
buffer was mixed with cocktail I (Roche) and Phenylmethylsulphonyl fluoride (PMSF) 
(Calbiochem) at ratio of 50:1 and 200:1 respectively. Fluorescence values have been 





Chapter 4: Results 
 
 
4.1 Cellular Selenium Content Assessment 
 
4.1.1 Delivery efficacy of Chitosan-Na2SeO3 
Chitosan-Se and original Se were applied to HCT-116 at doses of 0.3, 1, 3, 10 μM. In 
accordance with Figure 4.1.1, at doses of 0.3 and 1 μM, no significant difference of 
cellular Se concentration was observed among three types of selenium compounds. 
However, cellular concentration of L-Na2SeO3 was jumped to 400 at dose 3 μM and 1200 
μg/L at 10 μM, which meant higher delivery efficacy of L-Na2SeO3 compared to other 
two. The overall absorption of three Na2SeO3 types at dose 10 μM was above 500 μg/L 






















Figure 4.1.1 Cellular Se concentration in human colon cancer cells HCT-116. Absorption 
of three types of Na2SeO3 increased in a dose dependent manner. Among them, L-
Na2SeO3 exhibited most high delivery efficacy, which reaches up to 1200 μg/L. Na2SeO3 
is inorganic selenium compound; L-Na2SeO3 is encapsulated by low molecular weight 
chitosan; M-Na2SeO3 is encapsulated by medium molecular weight chitosan. 
 
In MRC-5, which is normal lung fibroblast cell, cellular Se content increased with dosage 
as shown in Figure 4.1.2. However, the overall absorption of three Na2SeO3 types 
dropped dramatically, which was no more than 40 μg/L, almost 1/30 compared that of 
HCT-116. Of note, Chitosan-Na2SeO3 exhibited higher delivery efficacy than uncoated 
one.  
 
Figure 4.1.2 Cellular Se concentration in human normal lung fibroblast cells MRC-5. 
Absorption of three types of Na2SeO3 in MRC-5 had similar trend as that of HCT-116. 
However, the absorption scale is much lower in comparison with HCT-116, the 
maximum concentration was no more than 40 μg/L. Among three types of Na2SeO3, M- 
Na2SeO3 showed higher efficacy in delivery. 
 























As illustrated in Figure 4.1.3 and Figure 4.1.4, in both cell lines, cellular content of 
MSeA compounds fell into similar range (2-40μg/L). To HCT-116, the cellular 
concentration of chitosan-MSeA was much less than that of chitosan-Na2SeO3, which 
meant deliver efficacy was dependent on selenium type. To MRC-5, delivery efficacy of 
chitosan-MSeA was same as chitosan-Na2SeO3, with slight decline.  Interestingly, the 
overall uptaking of chitosan coated ones was less, whereas uptaking of original form was 
more in HCT-116. This phenomenon can attribute to specific targeting of Chitosan-
MSeA to cancer cells and, therefore, promoted toxic effect and induced decreased cell 
viability. 
 
Figure 4.1.3 Cellular Se concentration in human colon cancer cells HCT-116. Absorption 
of three MSeA followed doses except no M-MSeA at 10 μM. Compared to Na2SeO3, 
deliver efficacy of MSeA decreased to 30 μg/L approximately. MSeA (Methylseleninic 
Acid) is organic selenium compound; L-MSeA is encapsulated by low molecular weight 






















Figure 4.1.4 Cellular Se concentration in human normal lung fibroblast cells MRC-5. 
Overall uptake of three types of MSeA was a little bit less than that of HCT-116 cells. 
Cellular concentration of L-MSeA reached 20%, which was highest compared to other 
two selenium compounds. However, unlike Na2SeO3, MRC-5 demonstrated similar 
uptaking scale of three MSeA compounds as HCT-116.  
 
4.2 Cell survival assay by MTT  
 
4.2.1 Chitosan-Na2SeO3 nanoparticles inhibit cell viability in colon cancer HCT-116 cells 
 
Cell survival rate was calculated as:  
(MTT absorption w/ treatment) X100%/ (MTT abosorption w/o treatment) 
According to Figure 4.2.1, 10 μM L-Na2SeO3 and M-Na2SeO3 reduced survival rate of 
HCT-116 to 30% and 40% respectively, which was higher than 20% induced by Na2SeO3 
only. Student two-tailed T-test has been used to compare Chitosan-Na2SeO3 and 
Na2SeO3. P<0.01 between L-Na2SeO3 and Na2SeO3, as indicated by ** in figure 4.2.1. 



















chitosan-encapsulated particles. In other words, partial release of chitosan-Se may 
attenuate expected toxic effect even with a high abosorption by cancer cells. Chitosan 
was applied to culture medium as background control, which exerted little toxic effect on 
viability of HCT-116. 
 
Figure 4.2.1 Cell survival rate interpreted from MTT assay in human colon cancer cells 
HCT-116. Cell survival rate of L-Na2SeO3, M-Na2SeO3 and Na2SeO3 decreased to 40%, 
30% and 20% approximately. L-Chitosan and M-Chitosan, showing >90% survival rate, 
were added as background control. L-Chitosan is low molecular chitosan w/o selenium; 
M-Chitosan is medium molecular chitosan w/o selenium.  
** Represents P<0.01, when compare chitosan-Na2SeO3 and Na2SeO3. 
 
MRC-5 had a dose-dependent decline in survival rate. The slope in Figure 4.2.2 was 
more flat in contrast to rapidly declined slope in Figure 4.2.1. The overall higher survival 
rate in chitosan-Na2SeO3 applied normal cells, which was approximately 50%, can be 































induced by chitosan-Na2SeO3, there was little difference produced by original Na2SeO3 
between cancer and normal cells. Chitosan applied to MRC-5 had reverse effect 
evidenced by approximately 85% viability under 10 μM. 
 
Figure 4.2.2 Cell survival rate obtained from MTT assay in human normal lung fibroblast 
cells MRC-5. Cell survival rate of L-Na2SeO3, M-Na2SeO3 and Na2SeO3 decreased to 
50%, 45% and 20% approximately. L-Chitosan and M-Chitosan, showing >80% survival 
rate, were added as background control.  
 
4.2.2 Chitosan-MSeA nanoparticles inhibit cell viability in colon cancer HCT-116 cells 
 
Based on Figure 4.2.3 and Figure 4.2.4, both cell lines incubated with three MSeA 
compounds exhibited survival rate ranges from 40-50% at dose 10 μM.  It can be 
































Chitosan-MSeA was more protective for normal cells, having 15% elevated survival rate 
at average than original MSeA.  
 
Figure 4.2.3 Cell survival rate obtained from MTT assay in human colon cancer cells 
HCT-116. Cell survival rate of L-MSeA, M-MSeA and MSeA decreased to 55%, 45% 
and 40% approximately. L-Chitosan and M-Chitosan, showing >90% survival rate, were 
added as background control. 

































Figure 4.2.4 Cell survival rate obtained from MTT assay in human normal lung fibroblast 
cells MRC-5. Cell survival rate of L-MSeA, M-MSeA and MSeA decreased to 65%, 45% 
and 40% approximately. L-Chitosan and M-Chitosan, showing >80% survival rate, were 
added as background control.   
 
4.3 ROS production of Chitosan-Se 
 
4.3.1 ROS production was stimulated by Chitosan-Se in cancer cell HCT-116 after 9- 
hour treatment 
 
ROS production was calculated as: 
(ROS emission w/ treatment)/ (ROS emission w/o treatment) 
According to Figure 4.3.1, 10 μM L-Na2SeO3 and M-Na2SeO3 stimulated ROS 
production to 15 and 16 folds respectively in HCT-116, higher than 7 folds by Na2SeO3 
only. For Chitosan-Na2SeO3 applied cells, the curve climbed rapidly at higher doses 3 































due to relatively higher releasing profile of chitosan-encapsulated particles at early stage 
of treatment (9 hours). L-Chitosan and M-Chitosan, showing <2 folds’ production of 
ROS, had little reverse effect as oxidative stress to HCT-116. 
 
Figure 4.3.1 ROS (Reactive Oxygen Species) production in human colon cancer cells 
HCT-116. ROS production of 9-hour treatment by L-Na2SeO3, M-Na2SeO3 and Na2SeO3 
increased to 15, 16 and 7 folds approximately. L-Chitosan and M-Chitosan, showing <2 
folds’ production of ROS, were added as background control.  
 
In contrast to the ascending trend of ROS production in HCT-116, ROS moderately 
decreased along with doses in MRC-5. Under 9-hour challenging, ROS production 
induced by L-Na2SeO3, M-Na2SeO3 and Na2SeO3 decreased to 2.75, 2.25 and 2 folds 
approximately, as illustrated in Figure 4.3.2. No obvious difference between Chitosan-
Na2SeO3 and Na2SeO3 was observed, yet there was distinguished Chitosan-Na2SeO3 
suppressed ROS production in MRC-5 in contrast to HCT-116. L-Chitosan and M-
Chitosan, showing <2 folds’ production of ROS, indicating that Chitosan did not 



























Figure 4.3.2 ROS production in human normal lung fibroblast cells MRC-5. ROS 
production of 9-hour treatment by L-Na2SeO3, M-Na2SeO3 and Na2SeO3 decreased to 
2.75, 2.25 and 2 folds approximately. L-Chitosan and M-Chitosan, showing <2 folds’ 
production of ROS, were added as background control.  
 
Applied with three MSeA compounds, HCT-116 and MRC-5 demonstrated same ROS 
production pattern as that of three Na2SeO3 compounds, in accordance with Figure 4.3.3 
and Figure 4.3.4. In HCT-116, ROS productions were 10, 17 folds produced with L-
MSeA and M-MSeA, in comparison to 4 folds by MSeA only. At this early stage, 
Chitosan-MSeA exerted elevated oxidative stress than MSeA in HCT-116. In MRC-5, 
ROS production was 2, 1, 2 folds approximately, indicating Chitosan-MSeA  did 






























Figure 4.3.3 ROS (Reactive Oxygen Species) production in human colon cancer cells 
HCT-116. ROS production of 9-hour treatment by L-MSeA, M-MSeA and MSeA 
increased to 10, 17 and 4 folds approximately. L-Chitosan and M-Chitosan, showing <2.5 
folds’ production of ROS, were added as background control.  
 
Figure 4.3.4 ROS (Reactive Oxygen Species) production in human normal lung fibroblast 
cells MRC-5. ROS production of 9-hour treatment by L-MSeA, M-MSeA and MSeA 
decreased to 2, 1, 2 folds approximately. L-Chitosan and M-Chitosan, showing <2 folds’ 

















































4.3.2 ROS production was inhibited by Chitosan-Se in cancer cell HCT-116 after 24-hour 
treatment 
 
Based on Figure 4.3.5, striking decreased of ROS production in HCT 116 was observed 
at later stage (24h). ROS production of 24-hour treatment by L-Na2SeO3, M-Na2SeO3 and 
Na2SeO3 decreased to 1, 1 and 3 folds approximately. Chitosan-Na2SeO3 exhibited 
relative stronger influence on elimination of ROS, evidenced by 1 fold compared to 3 
fold induced by Na2SeO3. As background control, Chitosan particles were not able to 
attenuate ROS in a time-dependent manner.  
 
Figure 4.3.5 ROS production in human colon cancer cells HCT-116. ROS production of 
24-hour treatment by L-Na2SeO3, M-Na2SeO3 and Na2SeO3 decreased to 1, 1 and 3 folds 
approximately. L-Chitosan and M-Chitosan, showing >5 folds’ production of ROS, were 
added as background control.  
 
On contrary, ROS produced by L-Na2SeO3 and M-Na2SeO3 in MRC-5, increased up to 4, 




























under Chitosan-Na2SeO3 could be more toxic to MRC-5, attributing to excess oxidative 
stress. Chitosan particles as control did not reverse the increased ROS. 
 
Figure 4.3.6 ROS production in human normal lung fibroblast cells MRC-5. ROS 
production of 24-hour treatment by L-Na2SeO3 and M-Na2SeO3 increased to 4, 5.5, but 
Na2SeO3 kept at 1 fold approximately. L-Chitosan and M-Chitosan, showing >4.5 folds’ 
production of ROS, were added as background control.  
 
In HCT-116, we can notice a similar pattern existing in MSAs compounds (Figure 4.3.7). 
ROS production of 24-hour treatment by L-MSeA, M-MSeA and MSeA decreased to 1 
fold correspondingly in a dose dependent manner. Nevertheless, Chitosan-MSeA 
attenuated ROS (1.25 folds) compared to MSeA (5 folds) in MRC-5 (Figure 4.3.8), 






























Figure 4.3.7 ROS (Reactive Oxygen Species) production in human colon cancer cells 
HCT-116. ROS production of 24-hour treatment by L-MSeA, M-MSeA and MSeA 
decreased to 1, 1 and 1 folds approximately. L-Chitosan and M-Chitosan, showing >5 
folds’ production of ROS, were added as background control.  
 
Figure 4.3.8 ROS production in human normal lung fibroblast cells MRC-5. ROS 
production of 24-hour treatment by MSeA increased to 5 folds, whereas L-MSeA and M-
MSeA produced 1.25 fold ROS. L-Chitosan and M-Chitosan, showing >4.5 folds’ 





















































4.4 Expression of pATM Ser-1981 
 
4.4.1 Chitosan-Se up-regulated pATM Ser-1981 expression in normal cell MRC-5 at 6h  
 
Theoretically, expression of pATM Ser-1981 is elevated in response to DNA double-
strand-break damage. In context of this study, oxidative stress and supernutritional level 
of selenium are potential stimulus for pATM Ser-1981 and associated ATM DNA 
damage repair pathway. Here we utilized immunofluorescence to examine celluar 
expression and distribution of total ATM and phoporylated ATM at Ser-1981 activated 
by selenium compounds.  
Photographs of MSeAs 6-hour treatment were taken as examples. As background control, 
chitosan only had no significant influence on activation of pATM ser-1981 neither in 
HCT-116 (Figure 4.4.1 A) nor MRC-5 (Figure 4.4.1 B). Percentage of pATM ser-1981 
positive cells was 10% in HCT-116 cell (Figure 4.4.1 C) and 65% in MRC-5 (Figure 
4.4.1 D) respectively. Percentage of pATM ser-1981 positive cells was 20% in HCT-116 
cell (Figure 4.4.1 E) and 30% in MRC-5 (Figure 4.4.1 F) respectively. Chitosan-MSA 
treated MRC-5 (Figure 4.4.1 D) demonstrated more intensive expression of pATM ser-
1981 than HCT-116 (Figure 4.4.1 C).  
In consistence with results got from ROS production, inhibited phosphorylation of Ser-
1981 by chiotsan-MSeA could not counteract with ROS production, and subsequently, 
ROS level of 9-hour treatment was elevated in HCT-116. Of note, chiotsan-MSeA 
exhibited 35% more positive cells in MRC-5 than MSeA only, in contrast to 10% less in 
HCT-116. Anti-ROS function of Chitosan-MSeA can be obtained through increased 





A     B      
           
 C         D      
          




Figure 4.4.1 Expression of total ATM and pATM ser-1981 after 6-hour treatment of 
Chitosan-MSeA. Blue signal represents nuclear; Green signal represents total ATM; Red 
signal represents pATM ser-1981; Three colours represent merged image A, B: 
Challenged by Chitosan only No significant expression of pATM ser-1981 was observed 
neither in HCT-116 or MRC-5.  C, D: Percentage of pATM ser-1981 positive was 10% in 
HCT-116 cell and 65% in MRC-5 respectively; E, F: Percentage of pATM ser-1981 
positive was 20% in HCT-116 cell and 30% in MRC-5 respectively. D taken from 
Chitosan-MSA treated MRC-5 demonstrated more intensive expression of pATM ser-
1981 than E from HCT-116. 
 
Photographs of MSeAs 24-hour treatment were taken as examples. As background 
control, chitosan only had no significant influence on activation of pATM ser-1981 in 
HCT-116 (Figure 4.4.2 A), yet moderate stimulation pATM ser-1981 of in MRC-5 
(Figure 4.4.2 B). Percentage of pATM ser-1981 positive cells was 95% in HCT-116 cell 
(Figure 4.4.2 C) and 35% in MRC-5 (Figure 4.4.2 D) respectively. Percentage of pATM 
ser-1981 positive cells was 20% in HCT-116 cell (Figure 4.4.2 E) and 90% in MRC-5 
(Figure 4.4.2 F) respectively. Chitosan-MSA treated MRC-5 (Figure 4.4.2 D) 
demonstrated more intensive expression of pATM ser-1981 than HCT-116 (Figure 4.4.2 
C).  
4.4.2 Chitosan-Se down-regulated pATM Ser-1981 expression in normal cell MRC-5 at 
24h  
 
In consistence with results got from ROS production, enhanced expression of 
phosphorylation of Ser-1981 by chitosan-MSeA eliminated ROS production, and 
subsequently, ROS level of 24-hour treatment was reduced in HCT-116.  However, no 
such protective role of chitosan-MSeA existed in MRC-5. Of note, chiotsan-MSeA 




in MRC-5. Anti-ROS function of Chitosan-MSeA can be observed through increased 
ATM activation in HCT-116 after 24-hour treatment.  
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Figure 4.4.2 Expression of total ATM and pATM ser-1981 after 24-hour treatment of 
Chitosan-MSeA. A, B: HCT-116 and MRC-5 were challenged by Chitosan only. No 
expression of pATM ser-1981 was observed in HCT-116, but 13% showed red signal in 
MRC-5.  C, D: Percentage of pATM ser-1981 positive was 95% in HCT-116 cell and 
35% in MRC-5 respectively; E, F: Percentage of pATM ser-1981 positive was 25% in 
HCT-116 cell and 90% in MRC-5 respectively. C taken from Chitosan-MSA treated 
HCT-116 demonstrated more intensive expression of pATM ser-1981 than D from MRC-
5. 
 
4.4.3 Quantitative results based on immunofluorescence images  
 
To further interpret phosphorylaton degree of ATM under each treatment, percentage of 
pATM Ser-1981 positive cell was calculated as follow. Among them, L-Na2SeO3 induces 
highly significant increase of pATM Ser-1981 in MRC-5 cells after 6-hour incubation. 
Since ATM is a DNA damage repair protein, we infer that L- Na2SeO3 may function with 
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Figure 4.4.3 Percentage of pATM Ser-1981 for 6-hour treatment. H represents HCT-116 
cells; M represents MRC-5 cells. P represents P value derived from t-test; * represents 
P<0.05; ** represents P<0.01.  Percentage difference between two cell lines was 
analyzed by Student T test, two tails, Type 3. 



















































































However, when incubation extended to 24 hours, MRC-5 exhibited autophosphorylation 
of ATM without interference of Se compounds, which was evidenced by control groups. 
MRC-5 had overall less positive cells, which was due to less DNA damaged.  In addition, 
the chitosan-Se led to higher positive cells than original compounds in HCT-116 than 






















































































Figure 4.4.4 Percentage of pATM Ser-1981 for 24-hour treatment. H represents HCT-116 
cells; M represents MRC-5 cells.  






Chapter 5 Discussion and Perspective 
 
 
5.1 Roles of selenium in cell absorption and cell viability  
 
For cellular Se content, Na2SeO3 compounds demonstrated overall 30-40 times higher 
efficacy to cancer cells than normal cells. However, MSeA compounds were delivered to 
both cells with slightly higher concentration scale in HCT-116. Among selenium 
compounds, low molecular chitosan-Na2SeO3 owned the highest delivery efficacy. For 
chitosan-MSeA, interestingly, the original MSeA was higher in HCT-116 at dose 10μM. 
It is possible that increased absorption of chitosan-MSeA causes more cell death, and in 
turn, less cell available for Se assessment. 
The MTT assay reveals a retained viability induced by chitosan-Se of both cells. In 
addition, the chitosan-Se is more protective than orginal Se, especially to normal cells. It 
may be explained by a suspended releasing profile of nanopartiles causes attenuated 
toxicity to cells. Besides, cell culture medium for HCT-116 with chitosan-Se was 
approximately 8.0 and that for MRC-5 was about 7.3. The alkaline solution may mitigate 
surface charge of chitosan and hence no improved deliver efficacy. 
 
5.2 Roles of selenium in activation of pATM Ser-1981 
 
 In combination of ROS production and pATM Ser-1981 activation, we figure out ROS 




selenium (10μM), especially chitosan-Se, is able to trigger activation of pATM Ser-1981 
in normal cells at early stage (6h), without significant influence in cancer cells. This 
activation of ATM probably trigger ATM-mediated DNA DSBs repair pathway and fight 
against further production of ROS. That is why ROS production at 9 hour was decreased 
in normal cells rather than in cancer cells. Moreover, chitosan-Se stimulated increased 
ROS in HCT-116, indicating it’s more toxic to cancer cells after 6-hour incubation. 
Again, effects of selenium have been reversed in both cells after 24-hour incubation. 
Chitosan-Se can activate ATM in cancer cell. Meanwhile, Chitosan-MSeA protected 
normal cells more than original one by generating less ROS.  Therefore, Chitosan-Se 
could facilitate cancer cells in DNA damage repair and elimination of ROS in 24-hour 





Selenium has been postulated as an antioxidant as well as an efficient chemopreventive 
trace element for cancer therapy. By incorporating into chitosan nanoparticles, its 
releasing profile and chemoproperties can be altered. This study investigated systemically 
in chemopreventive function of chitosan-Se and original Se in terms of cell viability, 
oxidative stress stimulation and activation of ATM, which is known as initiator of DNA 




By analyzing these parameters comprehensively, we found out that chitosan-facilitated 
delivery of Se to cancer cells, but still constrained to certain Se type and incubation time.  
Accurate releasing profile of chitosan-Se should be measured, in that absorption of 
chitosan-Se does not necessarily equals to complete cellular release of Se. Furthermore, 
time point set to MTT, ROS and immunofluorescence assessment should be optimized.  
To address potential function of chitosan-Se in ATM-mediated DNA damage pathway, 
we may also need to examine more factors, such as rH2AX and MRN complex, which 





















Appendix I: Chemicals and reagents 
10XTBS Bio-Rad 170-6435 
10XTG Bio-Rad 161-0771 
10XTBS Bio-Rad 170-6435 
10% SDS Teknova S0184 
Amphotericin B Mediatech 30003-CF 
Acetic acid Fisher 086636 
ATM antibody Epitomics YF-10-17-02C 
ATM Ser-1981 antibody Rockland 20772 
BSA Calbiochem D00069588 
Chitosan-Low molecular weight Sigma 448869 
Chitosan-Medium molecular weight Sigma 448877 
DAPI fluorescence staining dye Invitrogen 447892 
DMEM Cellgro 10-017-CV 
DMSO Mallinckrodt H31J18 
Essential amino acid Mediatech 25030-CI 
Ethanol (absolute) Pharmco AAPER C0910191 
EDTA Quality Biological 351-027-10 
Fetal Bovine Serum Sigma 028K0381 
Glycerol Sigma G-5516 
KCl Baker 4001-01 




MEM Mediatech 10010-CI 
MTT Calbiochem 475989 
Methanol Pharmco AAPER 0704046 
Methylseleninic acid Sigma 541281 
NaCl Baker 4058-05 
Na2 HPO4 Sigma S-7907 
NaOH Mallinckrodf 
Non essential amino acid Mediatech 25025-CI 
Non-Fat Dry Milk Bio-Rad 170-6404 
NP40 Calbiochem 492016 
Paraformaldehyde  Fisher 066298 
Penicillin-Streptomycin Cellgro 30-002-CI 
Phenylmethylsulphonyl fluoride Calbiochem D00006306 
Plasimocin InvivoGen MPT-31-005 
Protease inhibitor cocktail tablets Roche 12553900 
Puromycin Calbiochem 540222 
ROS dye (CM-H2DCFDA) Invitrogen 537553 
Secondary antibody-anti-mouse Introgen Alexa Fluor® 594 
Secondary antibody-anti-rabbit Introgen Alexa Fluor® 488 
Sodium tripolyphosphate (TPP) Pfalfz & Bauer S07555 
Sodium selenite Sigma S5261 
Tris-HCl Quality Biological 351-007-101 
Triton-100 Calbiochem D00014550 
Trypsin EDTA, 1X Cellgro 25-052-C 
Tween20 Calbiochem 655204 




Appendix II: Solutions and their ingredients 
10X PBS 80 g NaCl, 10 g KCl, 72 g Na2 HPO4, 12 g KH2PO4, 1 L dd H20 
MEM Cell culture medium 500 mL MEM medium, 15% Fetal Bovine Serum, 1% Penicillin-Streptomycin 
D-MEM Cell culture medium  
500 mL DMEM medium, 10% Fetal Bovine 
Serum, 100U/mL Penicillin-Streptomycin, 
100U/mL amphotericin B, 5μg/mL 
plasimocin  
Blocking buffer 3 g BSA, 100 mL PBS 
Lysis buffer 50 mM Tris-HCl (7.4), 250 mM NaCl, 5 mM EDTA, 0.1% NP40 
MEM cell culture medium 
500 mL DMEM medium, 10% Fetal Bovine 
Serum, 100U/mL Penicillin-Streptomycin, 
100U/mL amphotericin B, 5μg/mL 
plasimocin 
MTT 
 (0.083g MTT is dissolved in 10mL 100% 
ethanol as a stock concentration of  20mM) 
(serum free medium dilute 20mM MTT to 
1mM final) 
TBS-T 100 mL 10XTBS, 900 mL ddH20, 10 mL 10% Tween20 
 
Appendix III: Commercial kits 
BCATM Protein Assay Kit Thermo JI124811 
 
Appendix IV: Equipments and facilities  
Balance Denver Instrument S-403 




Cell culture incubator Thermo 3595 
FLUOstar OPTIMA BMG 413-3128 
Isotemp Air Bath Fisher 11-715-1250 
Isotemp Water Bath Fisher 15-462-01 
Legen RT centrifuge Thermo 75004377 
Optic Microscope Motic AE21 
Rocker VWR 12620-906 
Roto-Shake Genie Scientific Industries S1-1100 
Zeiss fluorescence microscope Carl Zeiss Axio Observer 100 
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